Johnson & Johnson
USUSDJohnson & Johnson (US:JNJ) — Biotechnology: Pharmaceutical Preparations. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 3. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
Over het Bedrijf
- Website
- jnj.com
- Beleggersrelaties
- investor.jnj.com/overview/default.aspx
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hoofdkantoor
- New Brunswick, United States
- CEO
- Joaquin Duato
- Werknemers
- 136 400
- Opgericht
- 1886
- Uitstaande Aandelen
- Free Float
- 2.41 mld.
- Marktkapitalisatie
- 655.37 mld. USD
- Insiders
- 0.05%
- Institutionele Beleggers
- 76.73%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsvorm
- XSNP
- ISIN
- US4781601046
- LEI
- 549300G0CFPGEF6X2043
- Uitkeringsratio
- 60.0%
- FCF
- 22.2 mld. USD57%
- Schuld
- 49.0 mld. USD1.3 jr FCF
- Dividendreeks
- 56+ jr
- Winst, FCF en uitbetaalde dividenden — voor de 12 maanden tot 28.06.2026 (het laatste rapport van het bedrijf).
Beschrijving
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Dividenden
Johnson & Johnson (JNJ) betaalt elk kwartaal dividend uit. Per jaar (12 maanden tot en met de laatst aangekondigde betaling): 5.28 USD per aandeel (betalingen: 4). Dat is ongeveer 2.00% van de huidige aandelenkoers. Op basis van de betalingsgeschiedenis wordt de volgende ex-dividenddatum verwacht rond 24.11.2026. Ononderbroken dividendgeschiedenis: 56 jaar.
| Ex-Datum | Uitbetaling | Bedrag | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-08-25 | 2026-09-08 | 1.3400 USD | 0.5/2.0 % | per kwartaal | US:JNJ |
| 2026-05-26 | 2026-06-09 | 1.3400 USD | 0.5/2.0 % | per kwartaal | US:JNJ |
| 2026-02-24 | 2026-03-10 | 1.3000 USD | 0.5/2.0 % | per kwartaal | US:JNJ |
| 2025-11-25 | 2025-12-09 | 1.3000 USD | 0.5/1.9 % | per kwartaal | US:JNJ |
| 2025-08-26 | 2025-09-09 | 1.3000 USD | 0.5/1.9 % | per kwartaal | US:JNJ |
| 2025-05-27 | 2025-06-10 | 1.3000 USD | 0.5/1.9 % | per kwartaal | US:JNJ |
| 2025-02-18 | 2025-03-04 | 1.2400 USD | 0.5/1.9 % | per kwartaal | US:JNJ |
| 2024-11-26 | 2024-12-10 | 1.2400 USD | 0.5/1.9 % | per kwartaal | US:JNJ |
| 2024-08-27 | 2024-09-10 | 1.2400 USD | 0.5/1.8 % | per kwartaal | US:JNJ |
| 2024-05-20 | 2024-06-04 | 1.2400 USD | 0.5/1.4 % | per kwartaal | US:JNJ |
| 2024-02-16 | 2024-03-05 | 1.1900 USD | 0.5/0.9 % | per kwartaal | US:JNJ |
| 2023-11-20 | 2023-12-05 | 1.1900 USD | 0.5/0.5 % | per kwartaal | US:JNJ |
Nieuws Deze Week
Persberichten van de investeerderswebsite van het bedrijf, dagelijks bijgewerkt. Links leiden naar de website van het bedrijf. De koppen zijn in de oorspronkelijke taal, zoals op de bedrijfswebsite.
Grootste Aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| BlackRock | 8.8% | 212.1 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 157.23 mln. | 2026-06-30 |
| State Street Corporation | 5.55% | 133.78 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 76.42 mln. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.67% | 64.37 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 62.38 mln. | 2026-06-30 |
| Geode Capital Management… | 2.45% | 59.09 mln. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.42% | 58.3 mln. | 2026-06-30 |
| Morgan Stanley | 1.86% | 44.81 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 32.48 mln. | 2026-07-31 |
| NORGES BANK | 1.32% | 31.83 mln. | 2026-06-30 |
| State Farm Mutual Automo… | 1.31% | 31.59 mln. | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 31.13 mln. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 29.45 mln. | 2026-08-31 |
| Northern Trust Corporati… | 1.19% | 28.79 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 22.91 mln. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 17.3 mln. | 2026-08-31 |
| VANGUARD SPECIALIZED FUN… | 0.56% | 13.53 mln. | 2026-04-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 13.07 mln. | 2026-06-30 |
| VANGUARD WHITEHALL FUNDS… | 0.39% | 9.48 mln. | 2026-04-30 |
| DUATO JOAQUIN BOIX (Chie… | ≈0.01% | 307 837 | 2026-08-13 |
| TAUBERT JENNIFER L (Offi… | ≈0.01% | 194 451 | 2026-08-17 |
| WENGEL KATHRYN E (Chief… | ≈0% | 114 659 | 2026-06-11 |
| WOLK JOSEPH J (Chief Fin… | ≈0% | 85 008 | 2026-02-17 |
| SCHMID TIMOTHY (Officer) | ≈0% | 26 251 | 2026-09-02 |
| SWANSON JAMES D (Chief T… | ≈0% | 25 698 | 2026-02-17 |
| REED JOHN C (Officer) | ≈0% | 24 911 | 2026-05-01 |
| DECKER ROBERT J (Officer… | ≈0% | 24 462 | 2026-02-27 |
| BROADHURST VANESSA (Offi… | ≈0% | 23 003 | 2026-07-20 |
| MULHOLLAND KRISTEN (Offi… | ≈0% | 19 830 | 2026-02-13 |
| The Vanguard Group | — | — | — |
